Whole-cell recordings and viral retrograde tracing in rats show that the interstitial nucleus of Cajal responds to ...
Laboratory electrophysiology, molecular simulations and mutational analysis identify an intersubunit transmembrane site ...
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...
Clinically approved drugs induced ChAT expression and acetylcholine production in podocytes in vivo, suggesting the pathway could be pharmacologically targeted.
A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis ...
The new research, published in ERJ Open Research, found that nearly one in five asthma patients and one in three COPD ...
Atropine and PAM for organophosphate poisoning.” Even if you remember the combination, do you ever get confused when asked ...
China NMPA approves Harbour BioMed’s BLA for batoclimab injection to treat generalized myasthenia gravis: Cambridge, Massachusetts Saturday, October 24, 2026, 17:00 Hrs [IST] Ha ...
HanAll Biopharma wins China approval for myasthenia gravis drug batoclimab China grants NMPA nod to batoclimab for gMG after ...
The FDA has approved the Zilbrysq autoinjector, a macrocyclic peptide C5 inhibitor and the first such administration option ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results